The protein atlas also identified NCBP1 (https://www.proteinatlas.org/ENSG00000136937-NCBP1/pathology (access on 25 November 2021)) as a favorable prognostic marker for prostate cancer and unfavorable for pancreatic cancer, while NCBP2 (https://www.proteinatlas.org/ENSG00000114503-NCBP2/pathology (access on 25 November 2021)) has been identified as an unfavorable prognostic marker for liver, pancreatic, and prostate cancer. Here, NCBP2 is linked to prostate carcinoma.